ETFs Morepen Laboratories Limited

MOREPENLAB

INE083A01026

Pharmaceuticals

Delayed Bombay S.E. 08:56:26 29/10/2026 +03			5-day change	1st Jan Change
119.65 ^INR	-4.96%		+1.44%	+191.33%

10-27	Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026	CI
09-28	Morepen Laboratories Limited Submits First U.S. ANDA For Sitagliptin Tablets USP	CI

ETFs positioned on Morepen Laboratories Limited

Name	YTD change	Weight	AuM
DIMENSIONAL EMERGING MARKETS CORE EQUITY 2 ETF - USD	+14.51%	-	9,273 M€
STATE STREET SPDR S&P EMERGING MARKETS SMALL CAP ETF - USD	+3.24%	0.02%	701 M€
STATE STREET SPDR PORTFOLIO EMERGING MARKETS ETF - USD	+6.41%	0%	17,649 M€
STATE STREET SPDR GLOBAL ALLOCATION ETF - DISTRIBUTING - USD	+6.61%	0%	317 M€
WARREN STREET GLOBAL EQUITY ETF - USD	+13.33%	0%	62 M€

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Fexofenadine, Montelukast (Oral), Montelukast (Chewable), Montelukast Sodium, among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen Nebulizer Model CN-11, Dr. Morepen Pulse Oximeter Model PO-12A, Dr. Morepen Breathe Free Vaporizer Model VP-06 and Dr. Morepen Pulse Oximeter Model PO-12A, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Employees

1,919

Sector

Pharmaceuticals

Calendar

11-14 Earnings release - Q2 2027

More about the company